Search is Powered by Google
Follow us on:
Follow our health news on Twitter
Follow Our News on Facebook
Personalization
login | register
Pharma Industry / Biotech Industry News

Xcelience Reduces Time To Phase I Studies By 17 Weeks Using API Into Capsule Services

Main Category: Pharma Industry / Biotech Industry
Also Included In: Clinical Trials / Drug Trials
Article Date: 12 Jun 2009 - 4:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

Xcelience, a leader in early drug development services, has developed a faster, more cost effective path to Phase I studies using Xcelodose® 600 and 600 S precision powder micro-dosing systems (Xcelodose® is a registered trademark of Capsugel® BVBA). API into Capsule projects are on average completed 45 percent faster than traditional formulation efforts, and in some specific cases we have saved our clients as much as 17 weeks.

"Today's molecule is under pressure," says Derek Hennecke, CEO and President. "We need to work smarter with clients to make the best choices, often with limited material. One of the best decisions we made was to put our money on Xcelodose ®. We were the first CRO in North America to do so, we've built up industry leading expertise, and this month we are proud to announce our 100th GMP batch."

"Our defined API into Capsule program is a true differentiator, but not the only one," adds V.P. Randall H. Guthrie. "Xcelience combines decades of drug development experience, state-of-the-art equipment, a strong audit history, and sound financial management to deliver solutions that enable our clients to rely on us to accelerate drug development programs and meet critical milestones."

Xcelience is also announcing a strategic expansion focused on areas of proven strength: low weight fills and potent compounds for API into capsule, continued expansion and growth of its formulation development team, implementation of UPLC analytical capability, investment in x-ray diffraction for preformulation activities, and blister packaging in support of client's clinical supply needs. Development of the purpose-built Grace Street expansion continues as planned.

Xcelience LLC, is a contract research organization which has been providing formulation development, preformulation, analytical, and clinical trial manufacturing since 1997. The company has a solid reputation for accelerating early development activities to speed potential drugs to clinical trials while applying stage-specific scientific knowledge and experience. Xcelience's unique corporate structure creates project teams that work intensively with each client, bringing an extension of their own organization into the Xcelience lab.

Source
Xcelience LLC




Personalized Homepage Weekly Newsletters Daily News Alerts
Hemophilia Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Please fill in our survey

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
NUCYNTA(TM) (tapentadol) CII Immediate Release Tablets Now Available For Relief Of Moderate To Severe Acute Pain
24 Jun 2009
Patients suffering from acute pain and healthcare professionals who treat pain have a new treatment option: NUCYNTA(TM) (tapentadol) CII immediate release tablets. This new medication for the relief of moderate to severe...


The Latest on LASIK
The Latest on LASIK

The latest technology gives doctors the ability to map the surface of a patient's eye. That unique map then guides the laser that reshapes the eye. But this technology comes at a price.

more videos are available in our health videos section.